Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi's naldemedine performs well in first COMPOSE Phase III

This article was originally published in Scrip

Executive Summary

Shionogi's naldemedine (S-297995), an investigational peripherally acting mu-opioid receptor antagonist, has met primary and secondary endpoints in a phase III study for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain receiving opioid therapy.

You may also be interested in...



Purdue Highlights Convenience Of New Opioid Induced Constipation Drug Symproic

With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.

Investing In People: Aligning VCs And Today’s Entrepreneurs

In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.

Deals Of The Year 2019 Winners Announced

Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...

Topics

Related Companies

UsernamePublicRestriction

Register

SC028276

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel